Table 1 Patient demographics

From: Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part

 

Cohort 1 ( n =3)

Cohort 2 ( n =3)

Cohort 3 ( n =4)

Cilengitide

500 mg

1000 mg

2000 mg

Median (range) age, years

56 (54–74)

43 (32–59)

57 (49–68)

Male

3

2

4

Female

–

1

–

ECOG performance status, n

   

0

2

1

1

1

1

2

3

  1. Abbreviation: ECOG=Eastern Cooperative Oncology Group.
Back to article page